Absence of antitumor effects of metformin in sorafenib-treated patients with hepatocellular carcinoma recurrence after hepatic resection and liver transplantation

BACKGROUNDS/AIMS: Hepatocellular carcinoma (HCC) recurrence following hepatic resection (HR) and liver transplantation (LT) remains a great concern. We assessed the antitumor effects of metformin in patients treated with sorafenib for HCC recurrence after HR or LT. METHODS: The two clinical retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Yong-Kyu, Hwang, Shin, Song, Gi-Won, Lee, Young-Joo, Kim, Ki-Hun, Ahn, Chul-Soo, Moon, Deok-Bog, Ha, Tae-Yong, Jung, Dong-Hwan, Park, Gil-Chun, Ryoo, Baek-Yeol, Lee, Sung-Gyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Hepato-Biliary-Pancreatic Surgery 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295365/
https://www.ncbi.nlm.nih.gov/pubmed/30588519
http://dx.doi.org/10.14701/ahbps.2018.22.4.297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295365/
https://www.ncbi.nlm.nih.gov/pubmed/30588519
http://dx.doi.org/10.14701/ahbps.2018.22.4.297

Ejemplares similares